NeoGenomics

Answers are in our DNA™

[NeoGenomics @NeoGenomics]

Today, we honor and express our deep gratitude to all the veterans who have served our country. Your bravery, sacrifice, and resilience inspire us daily. Thank you for your service.

#NeoGenomics #LifeAtNeo #WorkAtNeo #HiringOurHeroes #VeteransDay #VeteransDay26

[NeoGenomics @NeoGenomics]

Our expanding oncology IHC portfolio includes newly validated, off-the-shelf B7-H3, CD137, EZH2, PRMT5, and TROP2 biomarkers to help pharma partners make data-driven decisions that support patient selection, trial optimization, and clinical progress: https://t.co/27Mt4huzST

[NeoGenomics @NeoGenomics]

#NeoGenomics is proud to offer the c-MET CDx for NSCLC IHC testing to help oncologists and pathologists identify patients who may benefit from this breakthrough: https://t.co/ssIMzlXA19. c-MET is a new actionable biomarker with an FDA-approved targeted therapy for NSCLC patients.

[NeoGenomics @NeoGenomics]

Pathologists, laboratory leaders and industry partners: we’d love to connect at #AMP2026.

📅 November 10-14
🔗 Schedule time with our team: https://t.co/BdAhZniY8t.

#MolecularDiagnostics #Pathology #PrecisionOncology

[NeoGenomics @NeoGenomics]

Have a safe & happy Halloween!

#Halloween2026

[NeoGenomics @NeoGenomics]

Team Neo brought the creativity this week! 💚 From individual and group costumes to festive pets, we loved seeing everyone join in the fun for our annual #NeoGenomics costume contest!

#LifeAtNeo #NeoSPIRIT #WorkAtNeo

[NeoGenomics @NeoGenomics]

Today, #NeoGenomics announced third-quarter 2026 results, with total revenue increasing 11% year over year to $209 million and clinical revenue growing 13%, driven by NGS growth of 29%. To read the full #PressRelease, visit: https://t.co/femOdSYdIG

[NeoGenomics @NeoGenomics]

#BreastCancerAwarenessMonth is an important time to highlight tools supporting better #PatientCare. RaDaR® ST, which is indicated for use in #BreastCancer (https://t.co/dnghWTfrkq®st-mrd), is designed to support confidence across the cancer continuum of care.

[NeoGenomics @NeoGenomics]

#NeoGenomics Oncology Data Solutions team members are in Madrid, connecting with researchers, sponsors, and industry leaders to discuss the power of high-quality clinicogenomic data in oncology research at #ESMO2026.
📍 Booth #8028
🔗 Request a meeting: https://t.co/D2Aki20f59

[NeoGenomics @NeoGenomics]

The NeoGenomics Pharma and Oncology Data Solutions teams are excited to be in Madrid for #ESMO2026. Visit us during the congress at booth #8028 or request dedicated time with our team at: https://t.co/D2Aki20f59.

[NeoGenomics @NeoGenomics]

If you're at #ESMO2026, have you stopped by to learn how NeoGenomics supports oncology drug development with both advanced testing services and clinicogenomic data solutions? We're waiting for you! Meet our Pharma Services and Oncology Data Solutions teams at booth #8028.

[NeoGenomics @NeoGenomics]

By partnering with Epic Aura, NeoGenomics delivers genomic testing that fits naturally into Epic workflows, eliminating unnecessary manual steps and reducing errors tied to transcription and re‑entry.
🔗 https://t.co/l1CRuE642A

[NeoGenomics @NeoGenomics]

Looking for deeper insights to support your oncology program? Visit us at #ESMO2026 to learn how our Pharma Services and Oncology Data Solutions teams help biopharma organizations accelerate therapeutic development.

📍 Booth 8028
📅 October 23-27
🔗 https://t.co/D2Aki20f59

[NeoGenomics @NeoGenomics]

#NeoGenomics has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology: https://t.co/nx7urwlnLy.

[NeoGenomics @NeoGenomics]

#BreastCancerAwarenessMonth is an important time to highlight tools supporting better #PatientCare. RaDaR® ST, which is specifically indicated for use in #BreastCancer (https://t.co/dnghWTfrkq®st-mrd), is designed to support confidence across the cancer continuum of care.

[NeoGenomics @NeoGenomics]

Warren Stone, #NeoGenomics' current President and COO, has been appointed CEO and a member of the Board, effective January 4, 2027. ​

Tony Zook, current CEO and member of the Board, will transition to Executive Chair on January 4, 2027.

[NeoGenomics @NeoGenomics]

#BreastCancerAwarenessMonth begins today🎗️ All month long, we will be sharing education and resources, highlighting our testing solutions, and more.

#BreastCancerAwarenessMonth #BreastCancerAwareness2025 #CancerTesting #Oncology #NeoGenomics

[NeoGenomics @NeoGenomics]

Learning, growing, and leading together. 💙💚 Recently, leaders from across the organization came together at our HQ in Fort Myers, FL, for hands-on learning focused on business acumen and change resiliency.

#WorkAtNeo #NeoSPIRIT #LifeAtNeo

[NeoGenomics @NeoGenomics]

RaDaR® ST provides clear, actionable answers: https://t.co/uMhtb5Vj8d.

#NeoGenomics #RaDaRST #PrecisionOncology #MRD

[NeoGenomics @NeoGenomics]

RaDaR® ST helps pharma partners identify high-risk, ctDNA-positive patients, enriching your trial population for better outcomes. See how to stratify smarter with RaDaR ST: https://t.co/EfwvpdNxqD.